{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:10:10Z","timestamp":1781680210873,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Heart Foundation Post-doctoral Fellowship","award":["108288-2024_PDF"],"award-info":[{"award-number":["108288-2024_PDF"]}]},{"name":"National Health and Medical Research Council of Australia","award":["GNT 1160734"],"award-info":[{"award-number":["GNT 1160734"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The choice of starting antihypertensive regimen is important because most patients remain on their initial treatment, even when their BP remains high. We examined the expected BP lowering efficacy of antihypertensive regimens initiated among US Medicare beneficiaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data on a 20% random sample of Medicare beneficiaries aged \u226565 years with a diagnosis of hypertension. The initial regimen comprised all fills within 7 days of the first antihypertensive claim in 2023 with no fills in the previous 365 days. The primary analysis was restricted to regimens including \u22651 drug class recommended in the 2025 American Heart Association\/American College of Cardiology BP guideline and secondary analysis included all antihypertensive drug classes. Expected BP-lowering efficacy for each regimen was estimated using www.bpmodel.org, a model derived from 484 double-blind placebo-controlled randomized trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 52,031 Medicare beneficiaries initiating antihypertensive medications, 74% received monotherapy. In total, 1060 distinct drug combinations and 2836 unique drug-dose permutations were filled. The top 25 regimens accounted for 70% of initiations and conferred an average expected SBP reduction of 8 mm Hg and DBP of 4 mm Hg. When including non-guideline recommended antihypertensive regimens, the top 25 regimens were filled by 67% of patients initiating treatment, with an average expected SBP\/DBP reduction of 6\/3 mm Hg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most antihypertensive regimens initiated among US Medicare beneficiaries were low efficacy monotherapy. Initiating more effective antihypertensive therapy has the potential to improve BP control in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpag003","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:40:15Z","timestamp":1768999215000},"page":"921-930","source":"Crossref","is-referenced-by-count":1,"title":["Widespread use of low efficacy antihypertensive regimens for the initial treatment of hypertension among older US adults"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-5090","authenticated-orcid":false,"given":"Nelson","family":"Wang","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, UNSW , Sydney, NSW,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW,","place":["Australia"]},{"name":"Sydney Medical School, University of Sydney , Sydney, NSW,","place":["Australia"]},{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Chen","sequence":"additional","affiliation":[{"name":"Perisphere Real World Evidence, LLC , Austin, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, UNSW , Sydney, NSW,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of New South Wales , Sydney, NSW,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[{"name":"Perisphere Real World Evidence, LLC , Austin, TX,","place":["United States"]},{"name":"University of Alabama at Birmingham , Birmingham, AL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"2026061604110195500_hpag003-B1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/ajh\/hpae141","article-title":"Trends in blood pressure control among US adults with hypertension, 2013-2014 to 2021-2023","volume":"38","author":"Hardy","year":"2025","journal-title":"Am J Hypertens"},{"key":"2026061604110195500_hpag003-B2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"86","author":"Jones","year":"2025","journal-title":"JACC"},{"key":"2026061604110195500_hpag003-B3","doi-asserted-by":"publisher","first-page":"e028573","DOI":"10.1161\/jaha.122.028573","article-title":"Antihypertensive medication regimens used by US adults with hypertension and the potential for fixed-dose combination products: the national health and nutrition examination surveys 2015 to 2020","volume":"12","author":"Derington","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026061604110195500_hpag003-B4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/hypertensionaha.119.14360","article-title":"Trends in antihypertensive medication monotherapy and combination use among US adults, national health and nutrition examination survey 2005-2016","volume":"75","author":"Derington","year":"2020","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0140-6736(25)00991-2","article-title":"Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"2026061604110195500_hpag003-B6","first-page":"1087","article-title":"Therapeutic inertia with initial low-dose quadruple combination therapy for hypertension: results from the QUARTET trial","volume":"81","author":"Wang","year":"2024","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","article-title":"Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial","volume":"5","author":"Wang","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026061604110195500_hpag003-B8","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/HYPERTENSIONAHA.123.21901","article-title":"Initial antihypertensive prescribing in relation to blood pressure among Florida Medicaid and Medicare recipients in the OneFlorida+ research consortium","volume":"81","author":"Smith","year":"2024","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B9","doi-asserted-by":"publisher","first-page":"e036557","DOI":"10.1161\/jaha.124.036557","article-title":"Trends in initial antihypertensive medication prescribing among &gt;2.8\u2009million veterans newly diagnosed with hypertension, 2000 to 2019","volume":"13","author":"Xu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026061604110195500_hpag003-B10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/87551225211069802","article-title":"Prescribing patterns of antihypertensive agents and blood pressure control among patients with incident stage 2 hypertension","volume":"38","author":"Helms","year":"2022","journal-title":"J Pharm Technol"},{"key":"2026061604110195500_hpag003-B11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ajh\/hpab137","article-title":"Prescription patterns for the use of antihypertensive drugs for primary prevention among patients with hypertension in the United Kingdom","volume":"35","author":"Jiao","year":"2022","journal-title":"Am J Hypertens"},{"key":"2026061604110195500_hpag003-B12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","article-title":"Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens","volume":"77","author":"An","year":"2021","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B13","doi-asserted-by":"publisher","first-page":"e004188","DOI":"10.1161\/jaha.116.004188","article-title":"Treatment intensification for hypertension in US ambulatory medical care","volume":"5","author":"Mu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026061604110195500_hpag003-B14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","article-title":"Initial antihypertensive treatment strategies and therapeutic inertia","volume":"72","author":"Rea","year":"2018","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B15","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026061604110195500_hpag003-B16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026061604110195500_hpag003-B17","doi-asserted-by":"publisher","first-page":"e090440","DOI":"10.1136\/bmjopen-2024-090440","article-title":"Does mean systolic blood pressure less than 130 mm Hg ensure high rates of control to &lt;140\/&lt;90 mm Hg? A cross-sectional analysis of two cohorts","volume":"15","author":"Egan","year":"2025","journal-title":"BMJ Open"},{"key":"2026061604110195500_hpag003-B18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026061604110195500_hpag003-B19","doi-asserted-by":"crossref","first-page":"101883","DOI":"10.1016\/j.jacadv.2025.101883","article-title":"Low dose combinations with three or four blood pressure lowering medications for treatment of hypertension","volume":"4","author":"Wang","year":"2025","journal-title":"JACC Adv"},{"key":"2026061604110195500_hpag003-B20","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/hypertensionaha.122.19222","article-title":"Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020","volume":"79","author":"Muntner","year":"2022","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B21","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026061604110195500_hpag003-B22","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jacc.2025.08.063","article-title":"Treating with the goal in mind: the role of low-dose combinations","volume":"86","author":"Wang","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026061604110195500_hpag003-B23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1161\/hypertensionaha.122.20458","article-title":"Clinical utility of short-term blood pressure measures to inform long-term blood pressure management","volume":"80","author":"Wang","year":"2023","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B24","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jch.13933","article-title":"Regression to the mean in home blood pressure: analyses of the BP GUIDE study","volume":"22","author":"Wang","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026061604110195500_hpag003-B25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/HYPERTENSIONAHA.110.152421","article-title":"Monitoring initial response to angiotensin-converting enzyme inhibitor\u2013based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials","volume":"56","author":"Bell","year":"2010","journal-title":"Hypertension"},{"key":"2026061604110195500_hpag003-B26","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstr\u00f6m","year":"2023","journal-title":"JAMA"},{"key":"2026061604110195500_hpag003-B27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jclinepi.2008.07.018","article-title":"Mixed models showed no need for initial response monitoring after starting antihypertensive therapy","volume":"62","author":"Bell","year":"2009","journal-title":"J Clin Epidemiol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpag003\/66569480\/hpag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/7\/921\/66569480\/hpag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/7\/921\/66569480\/hpag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:11:08Z","timestamp":1781597468000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/7\/921\/8440751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag003","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,1,25]]}}}